Ratings by Baird (Jack Allen)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/3/2022 | Fate Therapeutics | FATE | New Coverage | Outperform (N/A) |
22.63 (33.82) |
49.45% | Details | |
| 6/3/2022 | Allogene | ALLO | New Coverage | Neutral (N/A) |
7.70 (17.25) |
124.03% | Details | |
| 6/3/2022 | Voyager Therapeutics | VYGR | New Coverage | Outperform (N/A) |
6.13 (6.07) |
-0.98% | Details | |
| 6/3/2022 | Homology Medicines | FIXX | New Coverage | Outperform (N/A) |
1.45 (2.76) |
90.34% | Details | |
| 6/3/2022 | Intellia Therapeutics | NTLA | New Coverage | Neutral (N/A) |
42.86 (67.74) |
58.05% | Details | |
| 3/9/2022 | Taysha Gene Therapies | TSHA | New Coverage | Outperform (N/A) |
5.74 (4.10) |
-28.57% | Details | |
| 12/3/2021 | Vor Biopharma, Inc. | VOR | New Coverage | Outperform (N/A) |
11.32 (5.40) |
-52.3% | Details | |
| 11/9/2021 | MiNK Therapeutics | INKT | New Coverage | Outperform (N/A) |
17.38 (1.71) |
-90.16% | Details | |
| 10/22/2021 | Decibel Therapeutics Inc | DBTX | New Coverage | Outperform (N/A) |
7.47 (4.33) |
-42.03% | Details | |
| 8/13/2021 | Instil Bio Inc | TIL | New Coverage | Outperform (N/A) |
16.27 (6.95) |
-57.28% | Details |
